Citron's Left to go short on Valeant again: TheStreet
(Reuters) - Andrew Left, who runs short-selling firm Citron Research, is planning to take a short position in Valeant Pharmaceuticals International Inc again, TheStreet reported.
Left's comments come a day after Sequoia Fund, which once was Valeant's largest shareholder, said it exited its position in the embattled Canadian drugmaker last month.
"They've sat down, and they've seen and they've interviewed and they walked," Left told TheStreet in an interview, adding that Sequoia has much more of an insider take into the company than the public.
"The fact they're selling tells everything." (bit.ly/29yH3O3)
Valeant has been under intense scrutiny for its business and accounting practices, sending its shares plummeting 91 percent from the record high of $263.81 it touched last August.
Valeant's troubles started after Citron accused it in October of using specialty pharmacies to inflate revenue.
The company has since shut down the specialty pharmacy.
Valeant, which appointed Joe Papa to replace Michael Pearson as CEO in May, has said it is open to selling major assets as the company tries to reduce its massive debt load of more than $30 billion.